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Abstract
Atomistic Molecular Dynamics provides powerful and flexible tools for the prediction and analysis of molecular and
macromolecular systems. Specifically, it provides a means by which we can measure theoretically that which can-
not be measured experimentally: the dynamic time-evolution of complex systems comprising atoms and mole-
cules. It is particularly suitable for the simulation and analysis of the otherwise inaccessible details of MHC-peptide
interaction and, on a larger scale, the simulation of the immune synapse. Progress has been relatively tentative yet
the emergence of truly high-performance computing and the development of coarse-grained simulation now
offers us the hope of accurately predicting thermodynamic parameters and of simulating not merely a handful of
proteins but larger, longer simulations comprising thousands of protein molecules and the cellular scale structures
they form. We exemplify this within the context of immunoinformatics.
Review
As Donald Knuth, the famous polymath of modern-day
computer science, wrote in the forward to the book “A
= B”: Science is what we understand well enough to
explain to a computer; Art is everything else we do.
Whatever its verity, this statement has a clear and com-
pelling appeal. The human mind, which has evolved
within the macroscopic world to understand macro-
scopic phenomena and predict macroscopic behaviour,
cannot completely grasp nor truly possesses a complete
intuitive understanding of the microscopic world of
atoms and molecules; a place which exists at the inter-
section of two worlds: the quantum world and the
world of conventional, large-scale physics. In venturing
to gain a scientific understanding of these elusive,
recondite worlds far beyond the limits of our direct
experience, we seek to do synthetic reductionism: dis-
secting phenomena associated with the nature and beha-
viour of the biological molecules comprising the systems
we study, and then building mathematical models
capable of predicting the more complex behaviour of
the systems emerging from these components.
It is only through accurate and robust prediction, that
we can be sure that we have attained any degree of true
understanding. The problem with bioscience in general
and immunology in particular is that our knowledge of
the basis of adaptive immunity is largely compiled from
indirect sources. Such sources include in vitro experi-
ments, which are performed in controlled yet often
highly artificial conditions far removed from the biologi-
cal context of the whole organism.
To a harsh eye and a harsh mind, the interpretation of
cellular function within the immune system is particu-
larly indirect and inferential, being largely based on the
use of flow cytometric detection of surface markers or
the cytotoxic or proliferative behaviour of a bulk popu-
lation of cells. All such experiments ultimately give
insight only in a most circuitous manner. To pass to the
practical, there has been much recent biomedical inter-
est expressed in computational tools for the analysis of
epitope-mediated immunogenicity [1-4]. The adaptive
immune system saves us from the death and disability
engendered by infectious disease. The adaptive immune
response functions to destroy invading pathogens.
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Effectively distinguishing foreign or non-self molecules
from host or self molecules is vital. One half is the
humoral immune response: antibodies, produced by B
cells, bind to antigens on the surfaces of invading
microbes. The cell-mediated immune response forms
the other half of adaptive immunity; here activated T
cells react against foreign antigen presented on the sur-
face of other cells.
Extensive, and continuing, work has been undertaken
to develop novel epitope prediction methods, based on a
variety of reliable and robust computational methods.
The main focus has been the quantitative prediction of
peptide-MHC interactions, the necessary precursor to
the recognition of epitopes by T cell receptors, and the
identification of continuous and discontinuous B-cell
epitopes [5-8]. Such approaches seek to combine the
best aspects of experimental and informatic science.
Informatics, in the form of immunoinformatics, thus
offers a considerable variety of tools and techniques for
undertaking the rapid, robust, and accurate computa-
tional identification of epitopes. By using such in silico
approaches, computer-based prediction methods can
significantly increase the celerity of T-cell and B-cell
epitope discovery, with a concomitant dividend for vac-
cine design and discovery. With an ever-increasing
number of pathogen genomes now available, the map-
ping of B-cell and T-cell epitopes, both computational
and experimental, is becoming a central issue in vaccine
discovery [9-17].
However, using epitope mapping and epitope predic-
tion makes understanding the structure or function of a
particular pathogen gene essentially irrelevant. Nonethe-
less, gaining insight into function can add value to the
exercise, allowing evolutionary rationales to be posited,
for example. Mapping or prediction works solely with
the physical structure of the protein, either in vivo,
in vitro, or in silico, and insights into the role played by
a protein in its organism of origin or within the context
of host-pathogen interactions are simply not needed.
By far the most successful prediction strategy has been
the data-driven prediction of T-cell epitopes. In a pivotal
retrospective analysis, Deavin et al. [18] compared sev-
eral early direct T-cell epitope prediction methods, with-
out finding a single method possessed of sufficient
accuracy to be deemed useful. T-cell epitope prediction
typically involves defining the peptide binding specificity
of specific class I or class II MHC alleles and then pre-
dicting epitopes in silico. Today work focuses on pre-
dicting class I MHC-peptide binding affinity. At least for
well-studied class I MHC alleles, such methods work
well [19,20].
However, for prediction of all immune epitope data
other than class I MHC peptide binding, results have
been unsatisfactory and substandard. Over the last few
years, several comparative studies have shown that the
prediction of class II T-cell epitopes is usually poor
[21-23]. Likewise, both structure- [24] and data-driven
[25] prediction of antibody-mediated epitopes have
again been shown to be poor. Moreover, irrespective of
the poor reported predictivity, there are several other
problems, albeit different for T-cell and B-cell epitope
prediction.
A quite different approach to obtaining predictions of
peptide:MHC binding is based on so-called molecular
dynamic simulation. This technique attempts to calcu-
late the free energy of binding for a given molecular
system, which is closely related to experimentally obser-
vable quantities such as equilibrium constants or IC50s.
It has the advantage that, in principle, there is no reli-
ance on known binding data, as it attempts the de novo
prediction of all relevant parameters given certain
knowledge of the system. Essentially, all that is required
is the experimentally determined structure, or a convin-
cing homology model, of a MHC peptide complex.
Explicit solvent Molecular Dynamics (or MD) is an
atomistic means of simulating the behaviour at room
temperature of one or more solute molecules, such as
an MHC protein, of defined geometry surrounded by an
environment of solvent and ions over a timescale of one
to several thousand nanoseconds. As we shall see below,
for a system evolving over time, MD provides an unsur-
passed and unsurpassable level of detail for all dynamic
behaviour.
What is molecular dynamics?
To answer this question fully is difficult, yet we can seek
to adumbrate at least a partial answer below. MD
describes in detail the individual and collective motion
of atoms within a molecular system [26]; thus MD can
provide a dynamic, rather than a static, picture of bio-
molecular systems. In the context of affinity and epitope
prediction, MD has the advantage that it is not data-dri-
ven, as it attempts the de novo prediction of all relevant
parameters given knowledge the system’s starting struc-
ture, be that an experimental structure or a convincing
homology model of ligand receptor complex. Unlike
other methods, MD can, in principle at least, account
for both explicit solvation and the intrinsic flexibility of
both receptor and ligand.
For large molecular systems comprising thousands of
atoms, many of the more sophisticated modelling tech-
niques, which often describe the potential energy surface
in terms of quantum mechanics, are too demanding of
computer resources to be useful. The Born-Oppenhei-
mer approximation states that the Schrodinger Equation
for a molecule can be separated into a part describing
the motions of the electrons and a part describing the
motions of the nuclei and that these two motions can
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be studied independently. MD is able to compute the
equilibrium position of a classical multiple body system.
It is assumed that the atoms of the system are con-
strained by an inter-atomic potential energy force field.
Each atom in the simulation is treated as a point mass
and Newton’s equations are integrated to compute the
motion of the N atoms comprising the system. Thus:
m
d r
dt
i
i
2
2 = Fi
mi is the mass of atom i, ri is the Cartesian 3-vector of
atom i, the second derivative of ri is the acceleration of
atom i, and Fi is the force vector acting on atom i. We
need only define the initial configuration of the system,
defining an initial set of atomic coordinates and setting
the initial atom velocities at random. At regular time
intervals thereafter, we are able to resolve the equation
of motion as represented by equations for each atom.
The forces on the atoms are calculated from the gradi-
ent of the potential energy function. The simulation
progresses as new positions and velocities are computed,
and the atomic coordinates updated.
Several algorithms exist for integrating the classical
equations of motion for these prodigious point swarms;
and include the Verlet algorithm, the velocity-Verlet,
and the leap frog algorithm. The time step chosen for
the integration should be considerably less than the fast-
est event simulated. About the fastest event is the vibra-
tion of a bond to hydrogen, which is of the order of 10
femtoseconds (fs); for comparison, a significant confor-
mational change or rearrangement will occur on a time
scale in the microsecond range. Thus hydrogen vibra-
tion sets an implicit scale for a minimum time-step.
When bonds involving hydrogen are not constrained in
simulations, the characteristic time-step will be 1fs.
When bonds to hydrogen are constrained, or the hydro-
gens themselves are not simulated explicitly, as is the
case for a so-called united atom model where hydrogen
atoms and their bonded heavy atom are treated as a sin-
gle interaction centre, then the time step can increase to
the order of 2-5fs.
To measure an observable quantity we must be able to
express this as the position in a phase space of dimen-
sion 6*N. The information within our system is largely
contained within the potential energy function, also
known as a so-called force field, which takes the form of
a simple penalty function for most atomistic biomolecu-
lar simulations. Molecules are treated as pseudo-
mechanical assemblies comprised of many simple
elements: atoms are modelled as spheres, bonds mod-
elled as rods, and bond and torsion angles modelled as
flexible joints. Thus force fields consist of harmonic
springs for bonds and bond angles, supplemented by
torsion profiles for dihedral angles. Atoms are modelled
as spheres, typically with constant point charges loca-
lized at the atomic centres. Terms which describe var-
ious types of interaction between atoms, including Van
der Waals and electrostatic, and possibly hydrogen
bonding, are also part of such force fields.
There are many extant force fields; biomolecular force
fields are intentionally parameterized to be multipurpose.
The most popular force fields include MM3 [27] for small
molecules, and GROMOS [28], AMBER [29-31], and
CHARMM [32,33] for proteins. Current force fields
remain imperfect, and developing more physically accurate
multipurpose polarization force fields is challenging. There
are doubtless many cryptic effects that are not dealt with
appropriately, such as salt or pH effects; there is therefore
a continuing effort to improve the description of intera-
tomic and intermolecular forces. Mono-valent ions and
solvent interactions are probably described adequately.
The backbone description would benefit from geometry-
dependent polarization and electrostatic terms. Divalent
ions are currently problematic for most force fields as
their first ligand shell is highly activated through polariza-
tion and charge-transfer; all such complex phenomena are
neglected by standard force fields. One means of addres-
sing this confounding issue is to combine quantum
mechanical effects into the MD simulation. We shall navi-
gate a brief discussion of this subject below.
As a technique, MD has for some time found use in
the prediction of the affinity or binding free energy
(ΔGbind) of macromolecular-ligand interactions [34].
Generally though, such endeavour has been instigated
and justified as demonstration of the potential of MD
rather than as routine tool delivering prospective rather
than retrospective predictions. There are many reasons
for this. One is the scepticism of experimentalists, reluc-
tant as they are to surrender their hegemony to the
computer. Another reason is the practicalities of routine
simulation on a scale large enough to be useful. Until
relatively recently, the computing resources necessary to
sustain simulations of sufficient size and duration to
obtain affinities has greatly restricted the general exploi-
tation of such techniques. In spite of this there has been
much interest in pursuing such a strategy, as MD has
the advantage that known binding data is unnecessary,
since the approach seeks to calculate all relevant para-
meters. For a simulation of a macromolecule-ligand
complex, all that is required is an initial experimental
protein structure, or a reliable homology model.
The definition of free energy (G), as derived from sta-
tistical mechanics, is framed in terms of the partition
function. This theoretical definition is however of little
practical value for most types of calculation. What one
can calculate more easily, however, is the free energy dif-
ference ΔGA->A’ between two states A and A’. In the
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vertical legs of Figure 1, states A and A’ are shown as the
peptides p1 and p2 complexed with an MHC in the
unbound state, and as TCR-p1-MHC and TCR-p2-MHC
complexes in the bound state. Methods exist able to eval-
uate these energy differences, each predicated on a differ-
ent set of assumptions and approximations [35]. The
semi-rigorous prediction of ΔGA->A’ can be approached
using free-energy-perturbation (FEP) calculations; or it
can be undertaken using thermodynamic integration
(TI). See Figure 1. The binding free energy difference
ΔΔGbinding can be calculated, which is more important as
it shows the relative affinities of two similar molecules A
(p1-MHC) and A’ (p2-MHC) binding to the same mole-
cule (TCR). These compute-intensive approaches use the
ensemble average of an energy function, which is itself a
function of the coordinates in configuration space.
Another strategy uses the horizontal legs in Figure 1
to calculate the binding free energy ΔGbind. Individual
free energies for the complex, the isolated ligand, and
the isolated receptor are calculated separately from MD
trajectories. The overall binding free energy is given by:
ΔG G G Gbind complex receptor ligand= − −
ΔGbind can be reduced to a set of contributions, each
defined so that cross terms can be neglected. Energetic
contributions are typically derived from a limited set of
structures rather than from extensive ensemble averages.
Entropic contributions arise from lost intra-molecular
flexibility and molecular motion. A continuum solvent
model solved using a linear Poisson-Boltzmann equation
replaces explicit electrostatic contributions made by
Figure 1 A thermodynamic cycle for free energy calculation. AB, A′B and A, A′ are the bound and unbound states of two different, but
similar molecules (shown here as peptides p1 and p2 complexed with MHC) binding with the same molecule B (shown as TCR). Here
ΔGBinding
P1 and ΔGBinding
P2 are the binding free energies of A and A′ to B, while ΔGBound
p P1 2→ and ΔGUnbound
p P1 2→ are the free energy
differences between the two molecules in their bound and unbound states, respectively. The vertical legs above are ‘alchemical’ paths which
transform one molecule into another, while the horizontal legs are ‘chemical’ paths which describe the binding process of one molecule to
another.
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water. Contributions made by non-polar atoms to the
desolvation energy are also calculated empirically.
A widely used example of such an approximate tech-
nique is the so-called MM/GBSA method [36,37], which
combines energies calculated using molecular mechanics
with implicit solvation models. Averaged properties are
calculated from a sampled MD trajectory, with entropic
contributions obtained using normal mode analysis.
Receptor-ligand complexes with significant structural
variation can be studied using this approach.
G E G TSmolecule MM sol= + −
where Gmolecule is the free energy of the complex, or the
isolated receptor, or isolated ligand; EMM is the energy
calculated from the MD trajectory using an empirical
force field; Gsol is the solvation energy; and -TS is the
entropic contribution. Angle brackets denote an average
over time, or another continuous parameter, in this case
an MD trajectory. When calculating the binding free
energy difference, it may be assumed that the standard
entropy change is similar for both models and can be
neglected. Other popular approaches to structural simu-
lation include the use of normal mode analysis (NMA)
[38], which obtains the simple harmonic motions of a
protein about local energy minima, or MC sampling [39].
Molecular dynamics simulations of the major
histocompatibility complex system
A considerable time has now passed since the first MD
simulations on an MHC-peptide complex were underta-
ken. During this time the availability if not the ease of
use of dynamic simulation has increased out of all
recognition [40]. Compared to some obscure proteins,
much work has been expended on simulating the Major
Histocompatibility Complex and its interaction with
peptides and the T-cell receptor; yet, when compared to
other, more famous proteins, relatively little work seems
to have been done. Researchers, experimentalists or the-
oreticians, are often loathed to abandon any system
which works for them.
Delisi and co-workers, were the first, or at least among
the very first, to make use of MD as a tool to explore
peptide-MHC binding. Subsequently, they developed
several different methods [41-52]. They partly focussed
on accurate docking using MD and partly on determin-
ing corresponding free energies. Didier Rognan also
made important early contributions in this area [53-58].
He found that the simulated dynamic properties of the
MHC-peptide complexes, such as solvent accessible sur-
face areas and hydrogen bonding patterns correlated
well with binding data. He could discriminate effectively
between tightly anchored binding peptides and weaker
non-binders.
More recently, several workers have begun using MD
methodology to analyse the characteristic features of
peptide-MHC complexes and to predict the dynamic
behaviour and thermodynamic stability of the system.
These methods have been used to evaluate Class I
[59,60] as well as Class II [61]. Painter et al. [62], fol-
lowing on from a study by Zacharias and Springer [63],
compared the peptide bound and non bound state of
the MHC molecule using molecular dynamic simulation
technology.
Yaneva et al. performed MD simulation studies of
HLA-DR3 with and without invariant chain-associated
peptide (CLIP); finding that larger conformational
changes of alpha-helices flanking the MHC binding
groove occur when CLIP is not present [64]. Addition-
ally, others have used the MHC as a suitably sized test
bed for developing novel aspects of MD methodology,
including both simulation methodology [65] and solva-
tion [66]. In such work, the MHC-peptide complex pro-
vides a convenient example of a binary molecular
complex. By combining MD simulation, peptide/MHC
binding assays, and T-cell activation, Knapp and co-
workers demonstrated that the N-terminal peptide
flanking region of class II MHC binding peptides signifi-
cantly enhances and modulates peptide immunogenicity
[67].
Michielin and Karplus [68,69] undertook a study that
made use of a whole array of a posteriori or post hoc
approximations to compute relative free energy differ-
ences between bound TCR-pMHC complexes with pep-
tides mutants. This approach used so-called
thermodynamic integration to calculate the free energy.
Despite the stated accuracy in its prediction, in many
ways this study was most unsatisfying, laden as it was
with unjustified methodological approximations: approx-
imations which could only have been applied if the
result was already known.
The study of Cuendet and Michielin [70] is a follow
up to this investigation. The characteristic half-life of a
TCR-pMHC complex can last several seconds: a time
far beyond the traditional range of atomistic simulation.
Their study afforded a new, if incomplete, insight into
the mechanism underlying disruption of the TCR-
pMHC complex, using a steered molecular dynamics
(SMD) protocol [71]. This is an example of non-equili-
brium dynamics, where the motion along the reaction
coordinate is progressively driven by an external poten-
tial. Such approaches include both the early targeted
MD studies of [72-74] and full SMD [75-82].
Our own work, spearheaded by Shunzhou Wan, repre-
sents efforts to address the potential of large scale MD,
allowing us to evaluate a series of increasingly complex
molecular systems [83-87]. Our simulations escalated
from an isolated MHC molecule [83], via the TCR-
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pMHC complex [84,85], where the computed structural
properties and thermodynamic binding parameters are
in good agreement with experiment, through to simulat-
ing a recognition complex comprising pMHC, TCR, and
a CD4 molecule embedded in two opposing patches of
membranes [87]. See Figure 2.
Since this TCR-pMHC-CD4 complex is the smallest
viable complex able to trigger transient calcium signal-
ling [88-91], this last undertaking is the first stage in
reaching our intermediate goal of simulating a full
immune synapse (IS): the adhesive junction formed
between T cells and professional antigen-presenting
Figure 2 the escalating scale necessary to simulate large-scale immunological phenomenon. (A) Model of the MHC alone, equivalent in
size to the simulation undertaken in [150]. (B) Model of the MHC complexed to the TCR, equivalent in size to the simulations undertaken in
[151]. (C) Complete model of a unit of the immune synapse, comprising MHC, TCR, peptide, CD4, and two opposing sections of membrane, as
simulated in [141].
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cells (APCs). The immune synapse plays a crucial role in
mediating initial immune recognition relaying informa-
tion from APC to T cell. This junction is a highly orga-
nized, spatio-temporal arrangement of receptors and
accessory molecules of many types. At least four key
kinds of molecules are involved in mediating the forma-
tion of the mature synapse [89,92]: lymphocyte func-
tion-associated antigen-1, intercellular adhesion
molecule-1, TCR, and the pMHC. The IS controls the
strength and duration of signals that can activate T
cells, and enhances the accumulation of peptide-major
histocompatibility complexes (pMHC) at the interface,
thereby enhancing engagement with TCR and subse-
quent cell signalling.
Experiments [92] have revealed the time frame in
which the IS forms, and the shape of the mature
immune synapse. The physical phenomenon has also
been modelled by reaction-diffusion equations and by
Monte Carlo (MC) simulation using statistical-mechani-
cal models [93-95]. However, little is known about the
spatial arrangement of individual molecules at the IS
[89,92], and how receptor clustering is orchestrated. A
complete view of the spatio-temporal dynamics of the IS
remains beyond current experimental methods. Multi-
scale molecular dynamic simulation may be the most
tractable way to gain a complete understanding of this
complex supra-macromolecular event.
This is the first step in a long journey which will
hopefully lead us to a full dynamic model of the
immune synapse. The immune synapse involves tens of
thousands of molecules not tens of thousands of atoms.
The timescale for its formation and maturation is about
30 minutes [92]. We have taken the next step by simu-
lating an extended model, in which 4 sets of TCR-
pMHC-CD4 complexes are included. This fully-atomis-
tic model, which includes explicit water and lipid mole-
cules, is approximately one million atoms in size. We
have undertaken 10 nanosecond MD simulations of the
system and the analysis is in progress. Mechanistic
insights relating to component interactions are gained
from such simulations. With further information on the
protein-protein and protein-membrane interactions,
extrapolation can be made to more and more realistic
IS models. Many insights can be gained from these
models about the dynamics of receptor binding and traf-
ficking and how these influence signal transduction by
endogenous and exogenous ligands.
Comparison of molecular dynamics to experiment
Generally speaking, MD simulations face two significant
limitations. First, the inadequate sampling of conforma-
tional space which reflects the short time scale of MD
simulations compared with those exhibited by biological
processes. This is being addressed by the continued
emergence of widely deployed supercomputing and
widely accessible parallel MD code. Second, despite
increasingly sophisticated parametrization, most, if not
all, empirical force fields remain highly approximate
[96-98]. We are thus still frustrated by concerns over
the intrinsic validity of such simulation exercises. Many
approaches have been tried to circumvent these pro-
blems, but only with limited success, since almost any
attempt to reach longer time scales will result in more
and more approximations.
Previous attempts to utilise MD to investigate peptide-
MHC interactions have foundered on technical limita-
tions. There is a tension between what we would wish
for and what is available to us. A race exists by which
the bigger the computing device we have, the bigger and
longer the simulation we wish to run. Since the scale of
biology is vastly greater than the largest realizable simu-
lation, it is a race which simulation always loses. Our
ambition invariably exceeds all possible achievement.
Many approaches have been tried to circumvent these
problems, but only with limited success, since almost
any attempt to reach longer time scales will result in
more approximations in the model. While many meth-
ods link thermodynamic properties to simulations, they
take an unrealistically long time. Moreover, there is a
need for long simulations able to accommodate both
slow and very fast – protein conformational change and
enzymatic transition states - motions seen in biological
simulations. Widely available serial computing has
allowed the MD simulation of biologically interesting
systems of moderate size. A basic free energy simulation
requires at the very least ten nanoseconds of simulation
time. This would take hundreds of hours per nanose-
cond of compute time on a desktop workstation. A
simulation of, say, a score of peptides might occupy a
whole machine for many years.
Thus there is a clear imbalance between generally-
available computing resources and the size of the task
to be evaluated. One way to address such an imbalance
is to use as large and as powerful a computer as one
possibly can. This necessitates the use of tightly-coupled
supercomputing to massively increase the computing
resources available, as distributed computing of the
screensaver type is simply not appropriate to MD
problems.
Distributed computing, most famously epitomised by
folding@home [http://folding.stanford.edu/], splits com-
puting jobs in separate, autonomous tasks and distri-
butes them across thousands or tens-of-thousands of
individual computing nodes, most usually unattended
personal computers left running out-of-hours. Foldin-
g@home and seti@home [http://setiathome.berkeley.
edu/] are amongst the largest distributed computing
efforts. Several kinds of computing study are readily
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addressable using such an approach, including certain
biomolecular simulations. For example, a 20,000 atom
simulation of the Villin Headpiece using 200,000 CPU’s
distributed around the world was run for a total of
500,000 nanoseconds in order to model the folding of
the protein [99]. Because the simulation was probing the
kinetic rather than thermodynamic properties of the sys-
tem, the use of many different, independent, short-term
trajectories run using CPU’s without real-time commu-
nication was wholly appropriate. An MD simulation
could not be run this way, only many copies of the
same simulation.
However, a series of competing but ultimately compli-
mentary technical advances has opened a potential new
if not yet properly realised era of accessible and widely-
deployed supercomputing. Supercomputing offers the
opportunity to circumvent logistic limitations by allow-
ing high performance, massively parallel implementa-
tions of MD codes to run on large integrated computing
systems with 512 or 1024 nodes.
However, the ready availability of dedicated, truly
large-scale supercomputing running from national cen-
tres is not what once was hoped. Several other alterna-
tives are, however, becoming more widely accessible.
These alternatives are partly composed of new comput-
ing platforms and partly of novel, seamless means of
deploying supercomputing capacity.
In the vanguard of such approaches has been the advent
about a decade ago of so-called GRID computing. This
refers to an ambitious if never fully realised effort to
develop an environment in which individual users can
access computers, databases and even experimental facil-
ities simply and transparently, without having to consider
the location or identity of such facilities. The GRID has
partly given way to the cloud computing. Cloud comput-
ing is a term for the delivery of modern-day internet com-
puting, yet maintains much commonality with a more
traditional client-server paradigm. Typical cloud comput-
ing provides applications accessed via web browsers, with
the underlying software and databases housed on servers.
Cloud is here used in an abstract and metaphoric sense,
and derives from the use of cloud drawings to represent
the underlying structure of complex networks, such as the
telephone system and the internet. Importantly, for com-
parison with GRID computing, details are supposedly
transparent with respect to users; users who are thus freed
from the need to understand, let alone gain expertise in,
the underlying technological infrastructure. This is a nat-
ural extension of the specialisation of Adam Smith’s pin
factory; knowledge becomes ever more specialised, to the
point where we need know only what we need to
know, and all else is done for us. Though why some disci-
plines gain a mystique - medicine or IT for example -
while others - such as car maintenance or scientific
research - do not, is harder to understand. Key is that
cloud computing provides resources via the Internet
which are dynamically scalable and often virtualized.
Another important development is the GPU. A GPU
or graphics processing unit contains large numbers of
arithmetic units able, amongst other things, to accelerate
greatly numerically intense MD simulation. It seems iro-
nic that science, from which emerged the business of
computing, has now become the poor relation to a
branch, albeit a lucrative branch, of the entertainment
industry. The coupling of modern GPU hardware and
GPU-specific programming languages has made exploit-
ing this technology relatively facile, and thus its deploy-
ment has burgeoned in the last few years. GPUs can
support efficient data-parallel algorithms that scale to
hundreds of tightly coupled processing units; an ideal
situation given the requirements of so much of MD
simulation. For example, GPUs greatly facilitate the eva-
luation of non-bonded interactions in MD simulations,
allowing performance over twenty times that of an iso-
lated CPU.
To a greater or lesser degree, software forms an
important part of almost all scientific research projects,
yet most specialist research software is only just fit for
purpose, at least when it is compared to equivalent pro-
grams available for the worlds of business. Much is
made of open-source software, and much is highly inno-
vative, but it is not developed to the high standards
expected of commercial software. Code is often hard to
understand and even harder to maintain and develop,
with inconsistent levels of documentation and little
orchestrated version control. Software designed to do
science, as opposed to say Microsoft products whose
use in science is secondary and incidental, is continu-
ously in the process of being either rewritten or written
again from scratch, as their programmers move onto
new employment on the ridiculously short three-year
post-doc turn around. This is a staggering waste of the
already grossly inadequate resources put into science in
general, and code-development in particular. MD code
suffers less than many areas in this regard, yet does not
escape the problem entirely, particularly when coming
to terms with parallelisation and the need to rewrite
code so that it can capitalise on potential improvements
in speed and efficiency. Increasingly, software, such as
NAMD [100-102], is specifically developed to run well
under parallelisation, making use of the enormous
innate synergy in efficient scaling. Older programs, such
as native CHARMM or AMBER, scale poorly and port-
ing them to a parallel environment has often proved
problematic.
Thus, computing power increases, and through such
innovation, will continue to increase in some sense for
the foreseeable future, yet this does not solve all
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problems, and many remain. However much computing
we have, we can always envisage simulations of a greater
size or duration and quickly exhaust whatever resource
we have available. Likewise, while running larger simula-
tions for longer does much to mitigate the effects of
inaccuracies of method, they cannot compensate
completely.
A force field’s performance relies on the mutual can-
celling of errors. This means that an energy penalty
function must be balanced in the system under study
and the parametrization must be accurate. If errors do
cancel, then the correct global minimum of the system
will be found: not all details are necessarily correct, but
the overall description is meaningful. The longer and
the larger the simulation, or the more qualitative the
answer sought, the more likely that such a situation will
be achieved. If errors do not cancel, a global minimum
will prove elusive; as a result the system will rapidly
degrade [103]. Clearly, longer and larger simulations,
such as those offered by supercomputers and similar
methodology, as described above, offer an equal benefit
in terms of parameterisation. As timescales and the total
size of simulations increase, the more likely we are to
get cancellation of errors. In essence, we will observe a
general, smoothing phenomenon: isolated temporary but
gross local errors, in space and time, will largely disap-
pear under the mass of more accurate observations
from the majority of the simulation.
Obviously, and bearing in mind what we have said
above, some well-judged sagacity is required to use the
results of MD simulations properly. If an accurate
experimental starting structure is available, MD can
often improve molecular interactions and local back-
bone and side-chain conformations. However, inadequa-
cies inherent with biomolecular force fields as well as
deficiencies in available sampling protocols mean that
MD cannot predict protein structures without experi-
mental input. Local conformational traps associated
with standard MD can be overcome by enhanced sam-
pling techniques, such as locally enhanced sampling,
replica exchange, or targeted MD [81,82]. Robust sam-
pling is also critical to obtain reliable results from free
energy calculations [104]. Unrealistic initial models will
typically become deformed by MD. If a structure has an
incorrect geometry confined by large energy barriers,
MD will not move it from its initial geometry.
Moreover, the MD trajectories that result from any
simulation should be compared rigorously with available
experimental data in order to assess both the accuracy
of the simulation and the implications of any structural
or calculated energetic change. Historically, the results
of simulations have always been compared to crystal
data. In this context, the analysis of a restricted subset
of atoms or simple root-mean-square distances may
mask problems. However, increasingly the results of lar-
ger and more sophisticated simulations must be com-
pared to other experimental data: typically either
thermodynamic quantities, such as affinities, or time-
dependent quantities, such as diffusion coefficients.
Although the immune system is hierarchical, and exhi-
bits much emergent behaviour, at its heart are straight-
forward molecular recognition events that are
indistinguishable from other types of biomacromolecular
interaction, such as those between antagonist and recep-
tor or enzyme and inhibitor. Epitope binding to an
MHC is, in terms of underlying physico-chemical phe-
nomena, identical to binding of small molecule drugs to
protein receptors. Isothermal titration calorimetry (ITC)
is a powerful technique to study protein-ligand interac-
tions: it is a method which measures stoichiometry
directly, making interpretation relatively and reasonably
facile [105-107]. Moreover, labelling, chemical modifica-
tion, immobilization, and competing molecules are not
required, making it both sensitive and rapid.
During binding, heat will be produced or absorbed.
ITC measures these heat changes directly, giving a com-
plete picture of a reaction’s thermodynamic parameters,
allowing the accurate determination of equilibrium dis-
sociation constants (Kd), stoichiometry (n), enthalpy
(ΔH), entropy (ΔS), and heat capacities (ΔCP). Thus ITC
goes beyond simply providing binding affinities, in the
form of equilibrium dissociation constants as other tech-
niques also do, and can help elucidate the underlying
molecular mechanisms of binding interaction. Such
insight is currently unobtainable using other binding
assays, such as surface plasmon resonance (SPR). ITC is,
at least for the majority of commonly encountered bio-
chemical reactions, quickly becoming the only real
choice for characterizing biomolecular interactions. It is
the only technique to measure binding enthalpy directly,
thus obviating the necessity of van’t Hoff analysis.
Obviously, since no technique is perfect, ITC will of
course impose its own restrictions, limitations, and
boundaries. The method can measure affinities but only
within a characteristic if wide range: 10-2 to 10-9 M; ITC
needs to make use of competitive binding, i.e. through
the displacement of weaker ligands, in order to measure
affinities below the nanomolar: 10-9 to 10-12 M. How-
ever, this highly automated technique doesn’t impose
unacceptable limitations on molecular weight, or the
choice of buffer, and can cope easily with turbid or
coloured solutions, including particulate ones.
Typically, a solution containing the ligand, such as a
peptide, is titrated into a solution of its receptor, for
example an MHC protein. The heat produced is moni-
tored over time. See Figure 3. Each peak is a heat
change when a small volume of the ligand is injected
into the ITC reaction cell. As the titrant increases, the
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heat change produced should be directly proportional to
the extent of binding. As the system becomes saturated,
heat changes dwindle, leaving only heats of dilution.
The binding curve can be deduced from this plot yield-
ing values for 1/Kd, n, and ΔH.
Our experience of ITC, though limited, indicates that
MHC proteins are indeed amenable to study by ITC.
We have looked at two systems – HLA-A*0201 and
HLA-C*0701 – and we observed significant heats of
binding. However, for reasons that have yet to yield to
an obvious rational explanation, the overall set of
experiments did not allow us to calculate dissociation
constants, nor entropies and enthalpies. Possibilities for
this abounded. The most compelling was that the sys-
tem may not have reached saturation, and that this may
result in part from a much more complex binding phe-
nomenon than has been supposed previously. Nonethe-
less, our results are consistent with the assertion that
ITC can generate a much more complete decomposition
of the peptide-MHC system than has been available pre-
viously. This provides a description which will be much
more useful for all types of prediction, but most espe-
cially for MD simulations and the richness of its output.
We are, given the opportunity, largely in place to predict
and measure the full range of thermodynamic features
of binding for the MHC-peptide system; only time and
resource stands between us and that tantalising
prospect.
Competing technologies: virtual screening,
quantum mechanics, and QM/MM simulations
Several other, similar computational techniques have
been applied to the MHC-peptide system. In the next
few paragraphs, we shall briefly survey some of the
more interesting and some of the more relevant. These
approaches form part of a spectrum of methods varying
enormously in complexity from simple molecular
descriptors, through empirical scoring functions, Poten-
tials of Mean Force, Force Field or Molecular Mechanics
Methods, MD and size-limited Quantum Mechanics,
and ultimately onto full scale QM/MM and Free Energy
perturbations.
In this transition from atom counts to full MD, there
is a remarkable amplification of required computing.
What we seek is some pragmatic solution to the accu-
racy gained vs time taken equation. The point at which
one stops on this spectrum is contingent upon the sys-
tem being evaluated, the number of peptides being eval-
uated, and the logistics of available computing power.
The term Virtual Screening (VS) derives from phar-
maceutical research, where it is used as an alternative to
high throughput screening: it uses predicted ligand-
receptor interactions to rank and/or filter molecules
[108]. Structure-based Virtual Screening is, in essence,
the repeated static docking - and subsequent empirical
scoring - of sets of small molecule structures to a bio-
macromolecular target. These sets can be substantial,
reaching the dimensions of databases. Some see VS as
simply verifying that molecules match the dimensions of
the binding site. Others doubt all attempts to use struc-
ture to enlighten the discovery of ligands. While argu-
ments regarding flexibility and large-scale
rearrangements seem compelling, they merely act as a
challenge to the discipline. Virtual Screening is a techni-
que with wide applicability and a burgeoning track-
record of success, at least in area of identifying small
molecule ligands of macromolecular targets, yet should
also help prosecute the identification of epitopes.
Speaking generally, and when viewed as a chronologi-
cal procedure, Virtual Screening can be separated into
five phases, beginning with the x-ray structure or
homology model of a target protein. This is combined
with potential agonists, antagonists, or inhibitors, or, in
our case, potential peptide epitopes. These should have
been carefully pre-screened for undesirable structural
characteristics inconsistent with those of known drugs.
The resulting set of ligands is then docked into a bind-
ing site model and scored for some appropriate correlate
of binding. This process should discriminate between a
small group of ligands with appreciable binding affinity
and the bulk of ligands which will lack the ability to
bind. The top handful of these ranked hits are selected,
bought or synthesized, and assayed experimentally. Like-
wise, the more sophisticated, and thus, generally, time
consuming, are our methods for evaluating the scoring
phase of the virtual screening process, the more likely
we are to screen accurately. If we want to dock a few
tens of structures, then we can afford to expend a great
deal of time on this process, but if our goal is to dock
Figure 3 Schematic of an ITC experiment. Evolution of an ITC
experiment; each arrow indicates a separate injection of ligand.
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the peptide fragments representing a whole genome,
then the practical limitations of computer time will
reduce this to a minimum.
Several workers have sought to apply VS to MHC-
peptide binding. Docking performs well when distin-
guishing potent ligands from non-ligands lacking all affi-
nity. However, it does poorly when predicting binding
affinity; particularly so for MHC binding prediction.
FRESNO is a now-ageing virtual screening methodol-
ogy developed by Didier Rognan. It relies on a simple
physicochemical model of peptide-MHC interaction
[109,110]. This model was trained using binding data
and experimentally-derived 3D structures for the MHC
alleles HLA-A0201 and H-2Kk. The inability to predict
binding constants directly from simulations, at least in a
short time, has led some to combine calculation with
statistics. Regression-based scoring is predicated on the
assumption that the total free-energy is approximated
by the sum of several separately-calculable contribu-
tions. Usually, regression coefficients are determined by
MLR, PLS, or some AI approach. An initial training set
of receptor-ligand crystal complexes and corresponding
experimental binding affinities is used to train the tun-
able potential energy function. As with all data driven
approaches, the contingent accuracy and the transfer-
ability to new congeneric series depends on the nature
of the training set.
Rognan and coworkers found that lipophilic interac-
tions contributed the most to HLA-A0201-peptide inter-
actions, whereas H-bonding predominated in H-2Kk
recognition. Cross-validated models were afterward used
to predict the binding affinity of a test set of 26 peptides
to HLA-A0204 (an allele closely related to HLA-A0201)
and of a series of 16 peptides to H-2Kk. They concluded
that their tuned scoring function could predict binding
free energies using these. More recently, Rognan and
colleagues found that, for predicting the binding affinity
of 26 peptides to the Class I MHC molecule HLA-
B*2705, FRESNO out performed six other, now rather
out-dated, methods. The success of FRESNO suggests
that optimising screening functions rather than using
totally generic versions may prove a successful route, at
least within a chemical area or protein family. This
chimes with our experience using virtual screening
approaches for MHC peptide binding prediction.
Turning now to bioinformatic based approaches,
others are using amino acid pair potentials, initially
developed to predict the fold of a protein, to identify
those peptides which will bind well to a MHC. Margalit
and Colleagues have proposed a number of virtual
screening methodologies [111,112], each of increasing
complexity. They used amino acid pair potentials, ori-
ginally developed by Miyazawa and Jernigan [113], to
evaluate the inter-protein contact complementarity
between peptide sequences and MHC binding site resi-
dues. They presented an analysis of peptide binding to
four MHC alleles (HLA-A2, HLA-A68, HLA-B27 and
H-2Kb), and were successful in predicting peptide bind-
ing to MHC molecules with hydrophobic binding pock-
ets but not when MHC molecules with charged or
hydrophilic pockets were investigated. Again focussing
on Class I alleles, a more recent study from this group
[114] used an updated set of statistical pairwise
potentials.
More recently, Davies and co-workers looked at a
large dataset of MHC-structures using static energetic
analysis following energy minimization, partitioning
interactions within the groove into van der Waals, elec-
trostatic and total non-bonded energy contributions
[115]. They found that the whole peptide defined speci-
ficity, highlighting the lack of dominant interactions
between peptide and MHC as there was no statistical
separation in the performance of a set of disjoint, yet
statistically-degenerate, models.
Class II has also been investigated using Virtual
Screening methods. For example, Swain developed a
threading method and applied it to Class II MHC pep-
tide interactions. More recently, Tong and co-workers
have used a virtual screening approach to address pep-
tide binding to the MHC allele HLA-Cw*0401 [116].
They concluded that class II anchor residues were not
restrictive, implying that binding pockets can house
many more peptide sequences than is supposed solely
from the prediction of anchor residues.
Within this context, two recent comparative papers
have analysed the limitations implicit within attempts to
predict this phenomena. Knapp et al. [117] combined
different tools for side chain substitution, energy mini-
mization, and interface scoring in an evaluation of class
I peptide-MHC binding. For a binary distinction
between non-binder and binder, their results varied con-
siderably with the protocol they used, with outcomes
ranging from near random, to accuracy of about 75%.
Zhang, Peters, and co-workers [118], assessed several
methods for class II MHC-peptide prediction showing
them to be better than random, but still markedly infer-
ior to best-in-class sequence-based prediction. They
conclude that their results are consistent with the idea
that only the use of measured binding data can yield
satisfactory results.
Sadiq et al. reported recently a Virtual Screening
approach that combines the core protocol behind VS
but with significant technical enhancements that bring
the full power of MD to bear on the problem [119].
They developed a highly automated workflow tool, their
Binding Affinity Calculator (BAC), for free energy rank-
ing, which enables them to automate and thus accelerate
the process of docking and performing binding affinity
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prediction. Their system uses fully atomistic molecular
dynamic simulations together with the well-understood
molecular mechanics Poisson−Boltzmann solvent acces-
sible surface area (MM/PBSA) free energy methodology,
enabling them to calculate the free energy of binding of
protein-ligand complexes.
Compared to empirical, molecular mechanics-type
potential energy functions, Quantum mechanics (abbre-
viated universally as QM) provides a much more accurate
physical description of atomic and molecular interaction,
which is, at the ab initio level at least, substantially free
of empirical parameterisation. It is well-known that
although it can offer systematic improvements in quality
by modulating atomic orbital basis sets and including
electronic correlation effects, Ab inito QM is still effec-
tively limited to gas-phase simulation of systems com-
prising no more than 30 to 50 atoms. Semi-empirical
QM, long used to simulate organic small molecules, can,
on the other hand, cope with much larger and more
complex molecular systems. Examples include MNDO
[120], AM1 [121,122], and PM3 [123,124].
However, it is not straightforward to extend QM cal-
culations to biomolecules, whose conformational space
arises from a complex spatial architecture of mutually-
compensating intra- and inter-molecular interactions.
Many biomacromolecules, including proteins and
nucleic acids, would experience a very robust electro-
static environment without the mitigating effects of sol-
vent screening. Unfortunately, the accurate modelling of
the dynamic behaviour of solvent lies outside the orbit
of current QM techniques. Here, the issue is not so
much the intrinsic performance of the QM methods
themselves, but deficiencies in the system being
modelled.
Until recently, Semi-empirical QM methods have been
little used to study proteins, mainly due to issues over
reproducing the geometries of large systems and the
heavy computational demands involved. From a QM
perspective, and despite their great size, two factors
make their simulation tractable: one is the lack of exotic
chemistry, such as are evinced by organo-metallic com-
pounds or transition elements, and the repetitive nature
of its polymeric structure, and thus their concomitant
intramolecular interactions, which allows for some sim-
plification of calculation. Obviously, proteins can con-
tain complexed metal ions but a large proportion do
not, and with the exception of proteins containing
metalloporphyrin heme and chlorophyll, many of the
subtle electronic effects encountered with transition
metals are absent.
Many attempts have sought to decrease the computa-
tional burden of using semi-empirical QM to model
proteins: for example, the divide-and-conquer method
[125], which, as its name suggests, partitions a protein
into components, a technique much applied to biochem-
ical systems [126-128]. Stewart reports the application of
the sophisticated semi-empirical QM method PM6 to
the simulation of several protein systems [129]. Here,
self-consistent field (SCF) equations were solved using
the so-called MOZYME method [130] rather than more
computationally demanding algorithms.
QM/MM, which stands for quantum mechanics/mole-
cular mechanics, is a hybrid approach supposedly com-
bining the accuracy of quantum mechanical calculations
with the speed of molecular mechanics. This allows the
study of very large, physically-realistic systems inaccessi-
ble to straightforward QM with a rigour inaccessible to
MM. Classical MD calculations are of the O(N2) while
ab-initio Quantum Mechanics calculations usually scale
O(N3) or worse. Another hybrid approach models the
“interesting” parts of a protein system using QM, and
the rest using MM. In our terms, the interesting region
of the system would correspond to the peptide binding
site of the MHC, and the rest would be the b2-micro-
globulin and a3 domains. Despite being compromised
by issues of defining, both accurately and tractably, the
boundary between the MM and QM regions of the sys-
tem being modelled, QM/MM, has nonetheless gener-
ated much interest [131]. Thus far only there has only
been one report of the application of QM/MM techni-
ques to the MHC system [132].
Towards useful and interesting molecular
dynamics simulations
Powered and empowered by the availability of super-
computing, cutting-edge MD simulations can now tackle
very large systems [133]. Most simulations of immuno-
logical systems have by contrast been small and meagre
efforts. Even the largest such simulation is small even
when compared to the state-of-the-art in biomolecular
simulations, which in themselves are very small when
compared say to the size of a cell or a sub-cellular
organelle.
However, assisted by rapid advances in experimental
imaging and quantitative proteomics, information can
now be garnered from simulations that are beginning to
approach the mesoscale rather than the scale of atoms
[134]; we no longer need to restrict ourselves to the dry
and uninteresting pico-second simulations of individual
proteins that were the meat and drink of yester year,
but can instead look to simulate in a reasonably realistic
way supramolecular systems and even biologically mean-
ingful cellular components.
In a simulation that would have taken a single desktop
computer over 35 years to undertake, a 1 million atom
MD simulation of the small, icosahedral plant virus
STMV, standing for satellite tobacco mosaic virus, was
run for 50 nanoseconds using NAMD [135]. In another
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study, this time comprising in excess of 2.64 million
atoms, the ribosome has been studied using MD
[134,136]. Rhodobacter sphaeroides photosynthetic units,
known to form inner membrane invaginations compris-
ing light-harvesting complexes, LH1 and LH2, and reac-
tion centres, have been simulated: large models
comprising 9 or 18 dimeric light harvesting 1 complexes
and 144 or 101 light harvesting 2 complexes, represent-
ing a total of 3,879 or 4,464 bacteriochlorophylls, were
evaluated [137]. Yet, perhaps the largest, and thus the
most interesting, structure amongst these large scale
simulations is that of the synaptic vesicle. It did not
start with a single x-ray structure or one built using
symmetry, but built the kind of complex, stochastic sys-
tem of which the cell is constructed. Using specially
derived measurements of protein and lipid composition,
vesicle size, density, and mass, a full structural model
was constructed and simulated using MD [138].
Simulations conducted on this scale will be vital in
trying to understand and successfully characterize the
structure of the catalogue of cellular pathways and net-
works emerging from proteomics, transcriptomics, and
other high throughput approaches to functional geno-
mics. Not simulations of precisely if inexactly defined –
or should that be exactly but imprecisely defined –
molecular structures, such as arise from X-ray or elec-
tron crystallography or multi-dimensional NMR. Rather,
simulations of large-scale, semi-stochastic structures
that define the ultra-structure of the cell. These simula-
tions may focus on protein complexes or the behaviour
of membranes, or of proteins concentrated within con-
fined spaces, of supramolecular complexes, such as pro-
teasome or inflammasome, or any of a hundred other
things.
Many of these examples are of a size and complexity
beyond the limits of current simulation technology.
There are two ways to address the discrepancy between
our aspirations and what is pragmatically close-at-hand:
one is coarse-graining and the other is the deployment
of petascale computing. Petascale is the new high-fron-
tier of supercomputing. Recently, Saksena et al. [139]
have reported the application of so-called petascale
computing resources to computational science research
in order to achieve results on an unprecedented scale, at
an unprecedented resolution, and at an unprecedented
speed. Utilising the then largest supercomputer in the
world open to scientific research, they reported a num-
ber of distinct applications, including several in biomedi-
cine, such as HIV and cerebrovascular haemodynamics.
By exploiting exceptional scaling performance on up to
32768 cores, they showed that parallel programming
with MPI is likely to be practical and useful when
undertaken at the petascale in the near to medium
future. More recently, they were able to extend this
work to simulations running on over 65636 cores run-
ning via the IBM Blue Gene/P system. However, despite
such prodigious feats, access to such systems remains
highly restricted and thus simultaneously utilising other
approaches remains a pragmatic strategy.
However, to have any chance of modelling some of
the larger structures we list we must make recourse to
the restrictions that very large scales imply, necessitating
the use of both coarse-graining and simulation on a
hierarchy of length and time scales. A wider spectrum
of length and time scales can be reached by coarse-
grained descriptions of large-scale phenomena [140].
MD simulation, with coarse-grained descriptions, is the
only currently available method that can provide spatio-
temporal information on large cellular systems [86,141].
Such a mesoscopic model would model each protein
or each protein domain as a soft ellipsoidal particle. In
such a model, the number of particles is dramatically
reduced and a microsecond time step replaces the fem-
tosecond one characteristic of MD. This will make tract-
able much larger and longer simulations. Other
approaches make use of hybrid techniques that model
the dynamics of macromolecules in solution by coupling
equations which account for fluctuating hydrodynamics
with MD describing the macromolecule.
Water and lipid molecules are represented implicitly.
Langevin dynamics, in which two additional force terms
have been added to Newton’s second law, account for
omitted degrees of freedom [142]. One term represents a
friction force which is proportional to the particle’s velo-
city and is oppositely directed; the other is a stochastic
term associated with the thermal motions of solvent and
lipid molecules. A potential energy function is built
which relates structure to energy and force, based around
the use of the Gay-Berne potential [143], a generalized
Lennard-Jones potential for ellipsoid particles. However,
potential functions are useless until their parameters are
optimized to represent real systems, here extant work is
often used on the inter-molecular interactions of macr-
molecules [87], to derive the parameter optimisation.
Such simulations not only provide the pair-wise interac-
tion forms in the effective potential, but also parse the
interplay between the components involved in the
immune response. The association and dissociation rate
constants from experiments [90] would verify parameters
obtained from simulation. See Figure 4.
Our coarse-grained particles move on the surfaces of
lipid bilayers, a quasi two-dimensional environment.
Lipid bilayers and solvent waters are modelled implicitly
as a continuum to provide an effective potential, a fric-
tion drag, and a heat bath. The collective dynamics and
elasticity of membranes affects the translation and loca-
lisation of proteins. The mature immune synapse, which
is characterized by a stable distribution of membrane
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proteins, consists of two functional domains: a central
cluster of TCR-pMHC complexes and a surrounding
ring of adhesion molecules. Two segregated patterns in
the junction are favourable because of the reduced ener-
getic cost of bending the cell membranes to accommo-
date two pairs of rings separately. The differences in
length between these regions create a functionally
important supramolecular structure at the mesoscale
and beyond. Inspection of such models allows effective
comparison simulation with experiment, though in this
case experiment results would be provided by real-time
confocal microscopy rather than the time and space
averages offered by x-ray crystallography. An effective
potential term [144] represents the global deformations
of the two cells at the junction. A good membrane
potential including the bending elastic energy of lipid
membrane is critical to mimicking the spontaneous cur-
vature of the bilayer.
In summary, we can say with confidence that, even-
tually if not quite tomorrow, as more sophisticated
methods evolve and develop, and MD becomes a widely
and habitually used tool, science will, in concert with
richer and improved measured data, develop ever more
accurate and predictive simulations of biological relevant
systems modelled at length and time scales appropriate
to the problem. MD will ultimately break free from the
many restrictions imposed by the limited data we cur-
rently possess by affording us the opportunity of true de
novo prediction of equilibrium binding kinetic constants.
Beyond that we envisage running simulations that pose
biological questions that can only be answered by
experiment, which in turn will drive the design of
experiments. The immunological synapse has been sug-
gested to be a therapeutic target [145]. The information
provided by these research initiatives gives unprece-
dented insight into the details of immune synapse for-
mation and structure that should, in turn, facilitate
development of new approaches to the design of vac-
cines and immunomodulatory drugs.
Conclusions
MD simulation [146] can be seen as a “virtual experi-
ment” where atoms and molecules interact under the
control of physical laws. The time evolution of atoms
Figure 4 Simulating the Immune synapse. (A) A detailed molecular model used for the initial simulation of the immune synapse comprising
CD4, peptide-MHC, TCR, and membrane regions [141]. (B) The same model as in (A), but this time it is shown fully solvated.
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within the system is followed by integrating their New-
tonian equations of motion. MD studies in biology have
proliferated rapidly in recent years [134,146] as an
important complement to experiment. These studies
enable science to learn something new, something that
cannot be found in other ways. MD simulations provide
the ultimate details of molecular phenomena and
enhance our understanding of biological function. It
enables us to measure effectively that which hitherto
was not measurable.
In terms of modelling the association of MHC mole-
cule with antigenic peptides, it is increasingly clear that
the whole peptide contributes to affinity, and thus to T
cell-mediated immunogenicity; effective models of bind-
ing must represent this adequately. This MD does impli-
citly, and our group has extensive and continuing
experience of developing reliable tools for this kind of
study. Using MD, we can both predict, and cyclically
manipulate, the affinity and thus the immunogenicity of
antigenic epitope peptides, in an allele-dependent
manner.
Many kinds of experiment have indicated the duration
of IS formation and the shape of the mature IS. Struc-
tural studies of molecules comprising the IS reveal ato-
mistically resolved yet static views of the individual
molecular recognition events involved. Reaction-diffu-
sion equations have been used to describe the spatio-
temporal evolution of intracellular protein
concentrations. Multi-scale MD simulations may be the
best opportunity we have to reach a full understanding
of this remarkable supra-macromolecular event at a cell-
cell junction. The scale of simulations has now reached
the point where these studies become possible. This is
due to the advent of high-end parallel platforms like
HECToR and grid infrastructure which achieves higher
throughput computing by taking advantage of many net-
worked computers.
Other than MD, many other approaches exist to model
the interaction between TCR, peptide, and pMHC or
between peptide and MHC. Various tools for both
sequence-based approaches and structure-based T-cell
epitope prediction are available [6,8,147,148]. However,
there is still much space for improving T-cell epitope pre-
dictions [23,149], especially structural T-cell activation.
Although MD approaches are increasingly seen as success-
ful, even by their former critics, many such techniques
retain the enduring limitations that have dogged atomistic
simulation of macromolecules since its inception. None-
theless, such techniques present us with an enticing ave-
nue to access detail not known or knowable from other
approaches. There is and will be a need to progress con-
stantly to larger and larger simulations and to use the
technique to drive rather than follow experiment.
While both MD and related methods hold out the
greatest hope for true de-novo predictions of MHC
binding, their present success rate is very much lower
than that of data driven models. However, as with most
of science, one must tease the genuinely useful from the
self-aggrandizing hyperbole. Much work remains to be
done on developing, refining, and applying this
methodology.
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